Document 0638
 DOCN  M9550638
 TI    The clinical application of recombinant erythropoietin in the
       HIV-infected patient.
 DT    9505
 AU    Glaspy JA; Chap L; Department of Medicine, University of California, Los
       Angeles; School of Medicine.
 SO    Hematol Oncol Clin North Am. 1994 Oct;8(5):945-59. Unique Identifier :
       AIDSLINE MED/95155192
 AB    Patients with HIV infection frequently develop clinically significant
       anemia, either as a manifestation of the HIV or as a result of therapy
       with medications such as zidovudine. Therapy with recombinant human
       erythropoietin can increase hemoglobin levels in these patients,
       decreasing transfusion requirements and improving some aspects of the
       quality of life. Once erythropoietin therapy is started, it is important
       to monitor patients carefully for the development of iron deficiency and
       erythrocytosis.
 DE    Anemia/COMPLICATIONS/DRUG THERAPY  Clinical Trials  Cost-Benefit
       Analysis  Erythropoietin/*THERAPEUTIC USE  Human  HIV
       Infections/COMPLICATIONS/*DRUG THERAPY/ECONOMICS  Recombinant
       Proteins/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).